Biology of Blood and Marrow Transplantation
Volume 14, Issue 2 , Pages 187-196 , February 2008

HLA-Identical Sibling Allogeneic Transplants versus Chemotherapy in Acute Myelogenous Leukemia with t(8;21) in First Complete Remission: Collaborative Study between the German AML Intergroup and CIBMTR

  • Richard F. Schlenk

      Affiliations

    • University of Ulm, Ulm, Germany
    • ,
  • Marcelo C. Pasquini

      Affiliations

    • Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, Wisconsin
    • Corresponding Author InformationCorrespondence and reprint requests: Marcelo C. Pasquini, MD, MS, Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, 8701 Watertown Plank Road, P.O. Box 26509, Milwaukee, Wisconsin, 53226.
    • ,
  • Waleska S. Pérez

      Affiliations

    • Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, Wisconsin
    • ,
  • Mei-Jie Zhang

      Affiliations

    • Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, Wisconsin
    • ,
  • Jürgen Krauter

      Affiliations

    • Hannover Medical School, Hannover, Germany
    • ,
  • Joseph H. Antin

      Affiliations

    • Dana-Farber Cancer Institute, Boston, Massachusetts
    • ,
  • Asad Bashey

      Affiliations

    • BMT Group of Georgia, Atlanta, Georgia
    • ,
  • Brian J. Bolwell

      Affiliations

    • Cleveland Clinic Foundation, Cleveland, Ohio
    • ,
  • Thomas Büchner

      Affiliations

    • University of Munster, Munster, Germany
    • ,
  • Jean-Yves Cahn

      Affiliations

    • Chu-Grenoble, Grenoble, France
    • ,
  • Mitchell S. Cairo

      Affiliations

    • Columbia University Medical Center, New York, New York
    • ,
  • Edward A. Copelan

      Affiliations

    • Cleveland Clinic Foundation, Cleveland, Ohio
    • ,
  • Corey S. Cutler

      Affiliations

    • Dana-Farber Cancer Institute, Boston, Massachusetts
    • ,
  • Hartmut Döhner

      Affiliations

    • University of Ulm, Ulm, Germany
    • ,
  • Robert Peter Gale

      Affiliations

    • Center for the Advanced Studies in Leukemia, Los Angeles, California
    • ,
  • Osman Ilhan

      Affiliations

    • Ibni Sinai Hospital, Ankara, Turkey
    • ,
  • Hillard M. Lazarus

      Affiliations

    • University Hospitals of Cleveland, Cleveland, Ohio
    • ,
  • Jane L. Liesveld

      Affiliations

    • University of Rochester Medical Center, Rochester, New York
    • ,
  • Mark R. Litzow

      Affiliations

    • Mayo Clinic, Rochester, Minnesota
    • ,
  • David I. Marks

      Affiliations

    • Bristol Children's Hospital, Bristol, United Kingdom
    • ,
  • Richard T. Maziarz

      Affiliations

    • Oregon Health Sciences University, Portland, Oregon
    • ,
  • Philip L. McCarthy

      Affiliations

    • Roswell Park Cancer Institute, Buffalo, New York
    • ,
  • Stephen D. Nimer

      Affiliations

    • Memorial Sloan-Kettering Cancer Center, New York, New York
    • ,
  • Jorge Sierra

      Affiliations

    • Hospital de Sant Pau, Barcelona, Spain
    • ,
  • Martin S. Tallman

      Affiliations

    • Northwestern University, Feinberg School of Medicine, Chicago, Illinois
    • ,
  • Daniel J. Weisdorf

      Affiliations

    • University of Minnesota, Minneapolis, Minnesota
    • ,
  • Mary M. Horowitz

      Affiliations

    • Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, Wisconsin
    • ,
  • Arnold Ganser

      Affiliations

    • Hannover Medical School, Hannover, Germany
    • ,
  • CIBMTR Acute Leukemia Working Committee

Received 14 June 2007 ,Accepted 22 October 2007.

  • Image Result

    Cumulative incidence of TRM after chemotherapy and HLA-matched sibling hematopoietic stem cell transplant for patients with t(8;21) AML in CR1, by postremission treatment.

    Cumulative incidence of TRM after chemotherapy and HLA-matched sibling hematopoietic stem cell transplant for patients with t(8;21) AML in CR1, by postremission treatment.

  • Image Result

    Cumulative incidence of relapse after chemotherapy and HLA-matched sibling hematopoietic stem cell transplant for patients with t(8;21) AML in CR1, by postremission treatment.

    Cumulative incidence of relapse after chemotherapy and HLA-matched sibling hematopoietic stem cell transplant for patients with t(8;21) AML in CR1, by postremission treatment.

  • Image Result

    Adjusted probability of RFS after chemotherapy and HLA-matched sibling hematopoietic stem cell transplant for patients with t(8;21) AML in CR1, by postremission treatment.

    Adjusted probability of RFS after chemotherapy and HLA-matched sibling hematopoietic stem cell transplant for patients with t(8;21) AML in CR1, by postremission treatment.

  • Image Result

    Adjusted probability of OS after chemotherapy and HLA-matched sibling hematopoietic stem cell transplant for patients with t(8;21) AML in CR1, by postremission treatment and presence of sex chromosome

    Adjusted probability of OS after chemotherapy and HLA-matched sibling hematopoietic stem cell transplant for patients with t(8;21) AML in CR1, by postremission treatment and presence of sex chromosome.

 The first two authors contributed equally to this article.

PII: S1083-8791(07)00528-9

doi: 10.1016/j.bbmt.2007.10.006

Biology of Blood and Marrow Transplantation
Volume 14, Issue 2 , Pages 187-196 , February 2008

Article Tools

* Image Usage & Resolution